BioCryst Pharmaceuticals (BCRX) Earns News Impact Rating of 0.14

News headlines about BioCryst Pharmaceuticals (NASDAQ:BCRX) have trended somewhat positive this week, according to Accern Sentiment. Accern identifies negative and positive press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. BioCryst Pharmaceuticals earned a news sentiment score of 0.14 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 46.034655628721 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s analysis:

Shares of BioCryst Pharmaceuticals (BCRX) opened at 4.53 on Friday. BioCryst Pharmaceuticals has a 12 month low of $3.75 and a 12 month high of $9.25. The company’s market cap is $364.34 million. The stock has a 50 day moving average of $5.36 and a 200-day moving average of $6.28.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.19) by $0.02. The firm had revenue of $3.10 million for the quarter, compared to the consensus estimate of $5.79 million. BioCryst Pharmaceuticals had a negative return on equity of 276.62% and a negative net margin of 160.97%. The firm’s revenue was down 35.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.22) EPS. Equities analysts forecast that BioCryst Pharmaceuticals will post ($0.72) earnings per share for the current year.

Several research analysts recently weighed in on BCRX shares. Zacks Investment Research raised shares of BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.75 price objective on the stock in a research note on Tuesday, April 18th. Noble Financial reissued a “buy” rating on shares of BioCryst Pharmaceuticals in a research note on Saturday, May 6th. Needham & Company LLC restated a “hold” rating on shares of BioCryst Pharmaceuticals in a report on Friday, May 19th. BidaskClub upgraded shares of BioCryst Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Tuesday, August 1st. Finally, HC Wainwright restated a “buy” rating on shares of BioCryst Pharmaceuticals in a report on Tuesday. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating to the company. BioCryst Pharmaceuticals currently has an average rating of “Hold” and an average price target of $8.00.

TRADEMARK VIOLATION WARNING: This story was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this story on another website, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The original version of this story can be read at

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.

Insider Buying and Selling by Quarter for BioCryst Pharmaceuticals (NASDAQ:BCRX)

What are top analysts saying about BioCryst Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for BioCryst Pharmaceuticals Inc. and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit